On November 17, 2026, Isomorphic Labs—an AI company focused on designing and developing new medicines—announced an oversubscribed $5 Billion Series C financing round. Valuation terms were not disclosed.

Investor Syndicate & Use of Proceeds

Co-Led by Greenoaks and Sequoia with Full Existing Investor Participation: The round was co-led by Greenoaks and Sequoia Capital, joined by Andreessen Horowitz (a16z) and several other new investors, alongside continued significant investment from Alphabet. All existing investors—Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund—also participated.

Scaling IsoDDE & AI-First Translational Infrastructure: Proceeds will accelerate scientific breakthroughs and proprietary AI advances, mature the IsoDDE engine across new biology, build global AI-led bioengineering infrastructure, and establish scalable AI-first translational and clinical development infrastructure to advance drug candidates toward clinical trials.

IsoDDE Engine & Preclinical Pipeline Progress

Positive Preclinical Results in Oncology and Immunology: Founded in 2021, headquartered in London with offices in Cambridge, Massachusetts and Lausanne, Switzerland, and led by Founder & CEO Sir Demis Hassabis and President Max Jaderberg, Isomorphic Labs builds its proprietary drug design engine IsoDDE—unifying foundational simulation AI models across therapeutic areas and drug modalities with proprietary reasoning agents. The company reported positive preclinical results across internal oncology and immunology programs as well as partnered programs, setting the stage for clinical entry.